| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Carbidopa and Levodopa extended release tablets are extended release combination of Carbidopa and Levodopa for the treatment of Parkinson's disease and syndrome.
|
Items |
Specification |
Results |
|
|
Character |
Appearance |
White to creamy white powder |
Creamy white powder |
|
Solubility |
Slightly soluble in water, practically insoluble in alcohol,ether. |
Meets the requirements |
|
|
Identification |
A,IR |
The spectrum of sample complies with the spectrum obtained with standard |
Complies |
|
RT |
Corresponds to the peak obtained with the standard |
Corresponds |
|
|
Specific rotation |
-21.0°~ -23.5° |
-21.8° |
|
|
Loss on drying |
6.9% ~ 7.9% |
7.2% |
|
|
Residue on ignition |
≤0.1% |
0.02% |
|
|
Heavy metals |
≤0.001% |
<0.001% |
|
|
Methyldopa |
≤0.5% |
0.30% |
|
|
Carbidopa related compound A |
≤0.5% |
Undetected |
|
|
Any other impurity |
≤0.10% |
0.06% |
|
|
Total impurities |
≤1.0% |
0.44% |
|
|
Residual solvents |
Meets the requirements. |
Meets the requirements. |
|
|
Assay |
98.0~102.0% |
99.8% |
|
Carbidopa with strong outer peripheral dopa decarboxylase inhibitors. Easy through the blood-brain barrier, in combination with levodopa, suppress only the outer peripheral dopa decarboxylase activity, reducing the generation of dopamine in peripheral tissues, reduce adverse reactions outer periphery, thereby enabling an increase in levodopa into the hub, improve brain dopamine concentration, enhance the efficacy of levodopa, it is an important adjunct to levodopa.
){kind=link}